This study is a randomized control trial assessing the impact of a simple evidence-based protocol for the treatment severe sepsis with hypotension in Zambia. This is a follow-up study to the Simplified Severe Sepsis Protocol (SSSP) study. The intervention protocol consists of a scheduled fluid regimen, early blood culture and antibiotics, and dopamine and blood transfusion when necessary. It is hypothesized that the protocol will significantly decrease in-hospital mortality in patients with severe sepsis and hypotension.
In recent years, evidence-based protocols of bundled therapies have improved survival of severe sepsis in developed countries. In sub-Saharan Africa, simple therapies such as IV fluids and early antibiotics are frequently under-utilized. Studies of fluid interventions in the region, however, have demonstrated conflicting results. Outcomes in septic patients may be further affected by delays in the diagnosis of tuberculosis-associated severe sepsis. The aims of this study are (1) To assess the impact on survival of a simple evidence-based protocol for severe sepsis with hypotensionor septic shock, (2) To evaluate the cost of implementation for a simplified severe sepsis protocol, (3) To develop a clinical diagnostic score for identifying tuberculosis in HIV positive patients with severe sepsis, and (4) To assess the performance of the Xpert TB/RIF rapid PCR system and urine lipoarabinomannan assay for diagnosing tuberculosis in HIV positive patients with severe sepsis.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
212
This protocol consists of an early aggressive fluid strategy, and, when appropriate, blood transfusion and titratable dopamine. Monitoring is based on physical exam findings.
Patients are managed according to admitting doctors' orders
University Teaching Hospital
Lusaka, Zambia
In-hospital all cause mortality
Time frame: During hospitalization, expected average 14 days
28-day all-cause mortality
Time frame: 28-day
In-hospital all cause mortality adjusted for illness severity
Adjusted for SAPS3 score
Time frame: During hospitalization, expected average 14 days
28-day all cause mortality adjusted for baseline illness severity
Adjusted for SAPS3 score
Time frame: 28-day
Cumulative adverse events
A composite outcome consisting of dopamine extravasation, dopamine-associated tissue ischemia or necrosis, iatrogenic pulmonary oedema, and transfusion-related adverse events.
Time frame: During hospitalization, expected average 14 days
Treatment cost per patient
A budget impact analysis will determine the cost of treatment per patient using a mix of direct measurements and micro-cost observation.
Time frame: During hospitalization, expected average 14 days
Antibiotic changed due to culture results
The proportion of patients whose antibiotic regimen was changed due to information obtained from blood culture results.
Time frame: During hospitalization, expected average 14 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.